Polypeptide-N-Acetylgalactosaminyltransferase 5 (GALNT5)
[Edit]Polypeptide GalNAc transferase 5; Protein-UDP acetylgalactosaminyltransferase 5; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 5
Hereditary multiple exostoses (HME) is an autosomal dominant condition in which bony outgrowths occur from the juxtaepiphyseal regions of the long bones. In a few percent of cases these exostoses undergo malignant transformation to chondrosarcomas.
One recent study has also reported that these proteins co-purify with glycosyltransferase (GlcA and GlcNAc transferase) activity and on that basis it has been postulated that they are themselves glycosyl-transferases. Significantly, both these interactions were abrogated by a disease-causing EXT mutation, indicating that they are important in the etiology of HME. The EXT2-GalNAc-T5 interaction provides the first direct physical link between EXT proteins and known components of glycosamino-glycan synthesis.
Organism species: Homo sapiens (Human)
CATALOG NO. | PRODUCT NAME | APPLICATIONS | |
Proteins | n/a | Recombinant Polypeptide-N-Acetylgalactosaminyltransferase 5 (GALNT5) | Recombinant Protein Customized Service Offer |
Antibodies | n/a | Monoclonal Antibody to Polypeptide-N-Acetylgalactosaminyltransferase 5 (GALNT5) | Monoclonal Antibody Customized Service Offer |
n/a | Polyclonal Antibody to Polypeptide-N-Acetylgalactosaminyltransferase 5 (GALNT5) | Polyclonal Antibody Customized Service Offer | |
Assay Kits | n/a | CLIA Kit for Polypeptide-N-Acetylgalactosaminyltransferase 5 (GALNT5) | CLIA Kit Customized Service Offer |
n/a | ELISA Kit for Polypeptide-N-Acetylgalactosaminyltransferase 5 (GALNT5) | ELISA Kit Customized Service Offer |
Organism species: Mus musculus (Mouse)
CATALOG NO. | PRODUCT NAME | APPLICATIONS | |
Proteins | n/a | Recombinant Polypeptide-N-Acetylgalactosaminyltransferase 5 (GALNT5) | Recombinant Protein Customized Service Offer |
Antibodies | n/a | Monoclonal Antibody to Polypeptide-N-Acetylgalactosaminyltransferase 5 (GALNT5) | Monoclonal Antibody Customized Service Offer |
n/a | Polyclonal Antibody to Polypeptide-N-Acetylgalactosaminyltransferase 5 (GALNT5) | Polyclonal Antibody Customized Service Offer | |
Assay Kits | n/a | CLIA Kit for Polypeptide-N-Acetylgalactosaminyltransferase 5 (GALNT5) | CLIA Kit Customized Service Offer |
n/a | ELISA Kit for Polypeptide-N-Acetylgalactosaminyltransferase 5 (GALNT5) | ELISA Kit Customized Service Offer |
Organism species: Rattus norvegicus (Rat)
CATALOG NO. | PRODUCT NAME | APPLICATIONS | |
Proteins | n/a | Recombinant Polypeptide-N-Acetylgalactosaminyltransferase 5 (GALNT5) | Recombinant Protein Customized Service Offer |
Antibodies | n/a | Monoclonal Antibody to Polypeptide-N-Acetylgalactosaminyltransferase 5 (GALNT5) | Monoclonal Antibody Customized Service Offer |
n/a | Polyclonal Antibody to Polypeptide-N-Acetylgalactosaminyltransferase 5 (GALNT5) | Polyclonal Antibody Customized Service Offer | |
Assay Kits | n/a | CLIA Kit for Polypeptide-N-Acetylgalactosaminyltransferase 5 (GALNT5) | CLIA Kit Customized Service Offer |
n/a | ELISA Kit for Polypeptide-N-Acetylgalactosaminyltransferase 5 (GALNT5) | ELISA Kit Customized Service Offer |
- "Complete sequencing and characterization of 21,243 full-length human cDNAs." Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
- "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
- "A direct interaction between EXT proteins and glycosyltransferases is defective in hereditary multiple exostoses."Hum. Mol. Genet. 8:2155-2164(1999) [PubMed] [Europe PMC] [Abstract]
- "Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions."Sci. Signal. 2:RA46-RA46(2009) [PubMed] [Europe PMC] [Abstract]
- "Initial characterization of the human central proteome."BMC Syst. Biol. 5:17-17(2011) [PubMed] [Europe PMC] [Abstract]
- "The consensus coding sequences of human breast and colorectal cancers." Science 314:268-274(2006) [PubMed] [Europe PMC] [Abstract]